Biopharma Research, Page 3 | Maven Bio

Skip to main content

Pfizer Q3 2025 Earnings Analysis: Portfolio Rebalancing Amid COVID Decline and Upcoming LOEs

Dec 17, 2025

HER2-Targeted Therapies Across Solid Tumors: Treatment Expansion and Earlier-Line Adoption in 2025

Dec 17, 2025

Merck Q3 2025 Earnings Breakdown: Keytruda Dominance, Vaccine Softness, and Pipeline Diversification

Dec 17, 2025

Inside Big Pharma's Portfolios: What Drove Q3 2025 Revenue

Dec 15, 2025

2025 Stock Performance of Top Pharmaceutical Companies: January 2–December 1

Dec 11, 2025

Advancing Beyond Statins: The Landscape of Emerging Cholesterol-Lowering Medicines

Dec 7, 2025

Gilead’s Q2 2025 Highlights

Aug 15, 2025

AI Tools for Life Sciences Investment Banking: A Diligence Workflow

Aug 7, 2025

US Biotech IPOs: H1 2025 Performance Update

Aug 6, 2025

Research your next biopharma question with Maven.

Request a trial